Detalles de la búsqueda
1.
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.
Int J Cancer;
152(6): 1243-1258, 2023 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36346290
2.
Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody-dependent HER4 intracellular domain trafficking.
Cancer Sci;
111(7): 2508-2525, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32415868
3.
Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples.
Br J Cancer;
122(3): 397-404, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31792349
4.
An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer.
Int J Cancer;
145(7): 1838-1851, 2019 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30882895
5.
ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells.
Cell Commun Signal;
17(1): 106, 2019 08 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-31443721
6.
Examination of HER3 targeting in cancer using monoclonal antibodies.
Proc Natl Acad Sci U S A;
112(3): 839-44, 2015 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25564668
7.
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
J Immunother Cancer;
12(1)2024 01 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38290768
8.
Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer.
Br J Pharmacol;
2023 Nov 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38030588
9.
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer.
Front Immunol;
14: 1168444, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37153618
10.
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies.
J Biol Chem;
286(13): 11337-45, 2011 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21282108
11.
Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.
Breast Cancer Res;
13(1): R17, 2011 Feb 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-21294885
12.
CD4 ligation excludes the Carma1-Bcl10-MALT1 complex from GM1-positive membrane rafts in CD3/CD28 activated T cells.
Cell Immunol;
270(1): 40-6, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-21489413
13.
Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures.
Cancers (Basel);
13(18)2021 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34572847
14.
Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells.
Sci Rep;
11(1): 2231, 2021 01 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33500516
15.
Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.
Int J Oncol;
59(1)2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34013359
16.
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models.
MAbs;
13(1): 1914883, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33876707
17.
A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
Theranostics;
11(13): 6173-6192, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33995652
18.
Anti-HER2 vaccines: new prospects for breast cancer therapy.
Cancer Immunol Immunother;
59(9): 1295-312, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20532501
19.
[The HER3/ERBB3 receptor: the dark side of the ERBB planet]. / Le récepteur HER3 ou ERBB3 - La face cachée de la planète ERBB.
Med Sci (Paris);
31(5): 465-8, 2015 May.
Artículo
en Francés
| MEDLINE | ID: mdl-26059291
20.
Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells.
Int J Radiat Oncol Biol Phys;
106(5): 1039-1051, 2020 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31959545